ALX Oncology
- Biotech or pharma, therapeutic R&D
ALX Oncology is a publicly traded, clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology's lead therapeutic candidate, evorpacept, is a highly differentiated potential best- and first-in-class CD47 blocker that targets and activates the innate immune system. In March, 2025 ALX announced an additional pipeline molecule, ALX2004 as a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platform. ALX2004 received IND clearance and is set to enter the clinic mid-year.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}